Wang Feng, Chen Gong, Zhang Zhen, Yuan Ying, Wang Yi, Gao Yuan-Hong, Sheng Weiqi, Wang Zixian, Li Xinxiang, Yuan Xianglin, Cai Sanjun, Ren Li, Liu Yunpeng, Xu Jianmin, Zhang Yanqiao, Liang Houjie, Wang Xicheng, Zhou Aiping, Ying Jianming, Li Guichao, Cai Muyan, Ji Gang, Li Taiyuan, Wang Jingyu, Hu Hanguang, Nan Kejun, Wang Liuhong, Zhang Suzhan, Li Jin, Xu Rui-Hua
Department of Medical Oncology, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China.
Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, P. R. China.
Cancer Commun (Lond). 2025 Mar;45(3):332-379. doi: 10.1002/cac2.12639. Epub 2024 Dec 31.
The 2024 updates of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the diagnosis and treatment of colorectal cancer emphasize standardizing cancer treatment in China, highlighting the latest advancements in evidence-based medicine, healthcare resource access, and precision medicine in oncology. These updates address disparities in epidemiological trends, clinicopathological characteristics, tumor biology, treatment approaches, and drug selection for colorectal cancer patients across diverse regions and backgrounds. Key revisions include adjustments to evidence levels for intensive treatment strategies, updates to regimens for deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) patients, proficient mismatch repair (pMMR)/ microsatellite stability (MSS) patients who have failed standard therapies, and rectal cancer patients with low recurrence risk. Additionally, recommendations for digital rectal examination and DNA polymerase epsilon (POLE)/ DNA polymerase delta 1 (POLD1) gene mutation testing have been strengthened. The 2024 CSCO Guidelines are based on both Chinese and international clinical research, as well as expert consensus, ensuring their relevance and applicability in clinical practice, while maintaining a commitment to scientific rigor, impartiality, and timely updates.
中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2024年版强调规范中国的癌症治疗，突出了循证医学、医疗资源获取以及肿瘤学精准医学方面的最新进展。这些更新涉及不同地区和背景的结直肠癌患者在流行病学趋势、临床病理特征、肿瘤生物学、治疗方法和药物选择上的差异。主要修订内容包括调整强化治疗策略的证据级别，更新错配修复缺陷（dMMR）/微卫星高度不稳定（MSI-H）患者、标准治疗失败的错配修复功能正常（pMMR）/微卫星稳定（MSS）患者以及低复发风险直肠癌患者的治疗方案。此外，还强化了直肠指检和DNA聚合酶ε（POLE）/DNA聚合酶δ1（POLD1）基因突变检测的推荐。2024年CSCO指南基于中国和国际临床研究以及专家共识制定，确保其在临床实践中的相关性和适用性，同时秉持科学严谨、公正和及时更新的原则。
Zotero 插件
